Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | LianBio | - | - |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 0.0 |
| Average | -1.83 |
|
LianBio is a science-driven biopharmaceutical company dedicated to developing and commercializing medicines for patients with unmet medical needs, with an initial focus on in-licensing assets for Greater China and other Asian markets. It is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease, and respiratory indications. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 5.91% |
| % Held by Institutions | 78.99% |
No data within this time range.
No data within this time range.
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 15 Mar 2024 | 13 Feb 2024 | 14 Mar 2024 | 4.8 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2024 | 4.80 | 1 | 1,811.32 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |